Portal de Periódicos da CAPES

Lymphocytes in Atherosclerosis

2015; Lippincott Williams & Wilkins; Volume: 35; Issue: 2 Linguagem: Inglês

10.1161/atvbaha.114.305144

1524-4636

Catherine C. Hedrick,

IL-33, ST2, and ILC Pathways

HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 35, No. 2Lymphocytes in Atherosclerosis Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBLymphocytes in Atherosclerosis Catherine C. Hedrick Catherine C. HedrickCatherine C. Hedrick From the Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA. Originally published1 Feb 2015https://doi.org/10.1161/ATVBAHA.114.305144Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:253–257Atherosclerosis is the major cause of cardiovascular disease, and cardiovascular disease remains the primary cause of death in the United States. The primary complication for patients with type 2 diabetes mellitus (T2D) is cardiovascular disease.1–8 Because the incidences of T2D and obesity are drastically increasing in the United States and now worldwide, understanding how atherosclerosis is accelerated in these diseases becomes even more important to discern.Although many scientific advances in research on atherosclerosis have been made by multiple groups during the past 30 years, particularly about the function of endothelial and smooth muscle biology and macrophage foam cell formation in atherosclerotic plaque development, the roles of immune cells in regulating atherosclerosis onset and progression are still being elucidated. It was widely thought that immune cells played little part in atherogenesis until 1986, when Hansson et al9–12 reported the presence of lymphocytes within atherosclerotic lesions; yet it was many years later until it was widely accepted that immune cells play an important role in atherogenesis.Since 1986, the viewpoint has changed significantly, but details on lymphocyte subsets and mechanisms are still emerging. Moreover, controversy still exists on the roles that some lymphocyte subsets play in atherosclerosis. These discrepancies in findings are at least partly because of differences in mouse models used, diet composition, and length of time on diet for atherosclerosis measurements. However, despite a few ongoing controversies, there are many studies on immune cells in atherogenesis in mice that show clear findings.10,12–23 For example, CD4+ T lymphocytes have been shown to accelerate atherosclerosis.18,24–29 Activated CD4 T cells can be distinguished based on their phenotype, and the predominant CD4+ effector T cells studied to date in the context of atherosclerosis are Th1, Th2, and Th17 cells. The Th1 cell, a CD4+ T effector cell that produces interferon-γ, is proatherogenic and abundant in atherosclerotic lesions.30 In contrast, few Th2 cells are found in atherosclerotic plaques,30 and their role in atherosclerosis remains unclear. Th17 cells produce interleukin (IL)-17A and IL-17F cytokines and have been localized to atherosclerotic lesions. However, the role of IL-17 in atherosclerosis remains somewhat controversial because there are published studies that support both a proinflammatory and anti-inflammatory role for this cytokine in atherogenesis.31–36 In contrast, CD4+Foxp3+ T regulatory cells (Tregs), a suppressive subset of T cells, have been shown to be highly atheroprotective in mice and this has been confirmed in multiple studies.16,17,19,20,37,38CD8 cells are much less studied in the context of atherosclerosis, but recent studies suggest that they may be proatherogenic39 although one recent study found that a CD8+CD25+ subset of CD8 cells may be atheroprotective.40 Expect to see more studies emerging on CD8 cells in atherosclerosis in the next few years as interest in this topic is expanding. Of note for further reading, a nice detailed review by Li and Ley41 on T cells in atherosclerosis with a focus on lymphocyte homing to aortic tissue was published this year in ATVB.Moreover, little is known about the role of innate-like lymphocyte subsets (natural killer cells [NK], γδ cells, and natural killer T cells [NKT]) in atherosclerosis. This article highlights studies on T- and B-lymphocyte subsets and innate-like lymphocyte subsets and their roles in atherosclerosis and related vascular diseases recently published in ATVB.T LymphocytesAs noted above, T-lymphocyte subsets have been found to play differing roles in atherosclerosis. Buono et al42 found that numbers of atheroprotective Tregs are reduced in atherosclerotic mice during high cholesterol diet feeding, and that this was a reversible process: on normalization of plasma cholesterol levels in the mice, Treg numbers were restored. Mechanisms for this are likely to be several, but these investigators found that high cholesterol diet feeding influenced Treg migration to aorta. Earlier studies have shown that the cholesterol content of lymphocytes affects their proliferation. Wilhelm et al43 reported in ATVB in 2009 that mice lacking apoA-I and functional high-density lipoprotein had increased atherosclerosis and increased cholesterol-associated CD4 T-lymphocyte proliferation and activation. Studies by Bensinger et al44 and also by our own group45 found that sterol content of lymphocytes increased their proliferation, and this was primarily regulated by the ATP-binding cassette transporter ABCG1. Whether the cholesterol content of Tregs directly affects their proliferation or function is not known, and the role that high-density lipoprotein may play in this process warrants further investigation.T regs may be also protective in other vascular diseases. In a recent study in ATVB, T regs were shown to protect against abdominal aortic aneurysm. In a well-established inducible mouse model of aneurysm using angiotensin II, selective depletion of Tregs using CD25 antibodies enhanced susceptibility of mice to aneurysm and promoted aortic rupture.46 Furthermore, these authors found that IL-10 played an important role in the protection against angiotensin II–induced aneurysm in this model. To address whether there is a link between T2D or obesity and lymphocyte function, recent work in ATVB shows that T-cell frequencies are changed in the adipose tissue of obese subjects. McLaughlin et al47 found that both visceral and subcutaneous fat depots in overweight and obese human subjects contained elevated numbers of both CD4 and CD8 T cells. Furthermore, these investigators found that Th2 frequencies in both fat pad depots correlated with reduced incidence of insulin resistance. Thus, adipose tissue of obese subjects likely contains cytokines and antigenic stimuli for modulation of T-cell numbers and activation. One possible mediator of increased T-cell recruitment to adipose tissue is the chemokine receptor CXCR3. In obese mice, CXCR3 expression was higher on stromal vascular cells of adipose tissue.48 CXCR3-deficient mice possessed fewer T cells in adipose depots and showed reductions in proinflammatory cytokines. A second novel mediator of T-cell infiltration and accumulation in adipose is CD11a, a β2 integrin. Jiang et al49 showed that CD11a is upregulated on CD8 cells from obese mice, and that CD8 T cells from CD11a-deficient mice failed to migrate to adipose tissue in vivo. This study is of interest because it supports a novel role for this integrin in lymphocyte homing to adipose tissue, which will be important for immunity associated with T2D and obesity.Despite accepted knowledge that lymphocytes significantly affect lesion development, we know little about the detailed mechanisms involved or the cross talk that occurs between myeloid cells and lymphocytes in the artery wall. Several studies in ATVB this year reported how novel cytokines and other novel T-cell modulators affected atherogenesis. For example, IL-19 is an anti-inflammatory cytokine produced by Th2 lymphocytes. Atherosclerotic-susceptible low-density lipoprotein receptor (LDLR)−/− mice treated with recombinant IL-19 developed less aortic atherosclerosis, and this was accompanied by polarization of CD4+ lymphocytes to a Th2 phenotype, with decreased interferon-γ and IL1β expression and increased expression of GATA3 and Foxp3 transcription factors.50 This study suggested that IL-19 was a potent inhibitor of atherosclerosis through its effect on T-cell polarization. Another novel molecule, T-cell immunoglobulin and mucin domain-3 (Tim-3), acts as a negative regulator of immune responses. In a recent report in ATVB, treatment of mice with anti-Tim3 antibody depleted Tim-3 and increased lesion development.51 This was accompanied by increased numbers of activated CD4+ effector T cells and reduced numbers of Tregs. Related to Th2 polarization is a recent study in humans that indicated that increased numbers of Th2 lymphocytes in blood was associated with reduced risk of myocardial infarction,52 suggesting that Th2 bias may indeed be atheroprotective.Macrophages and dendritic cells (DCs) are known to present antigen to T cells and also to secrete cytokines that participate in T-cell phenotypic switching in the vascular microenvironment. Three studies published recently in ATVB cite new mechanisms by which myeloid cells influence T-cell activation in atherosclerosis. One interesting article, in particular, relayed findings where oxidized LDL, but not native LDL, stimulated DC activation.53 These oxidized LDL–stimulated DC were able to induce T-cell proliferation and activation, and these DC polarized the CD4 cells to a Th1 or Th17 bias. Mechanistically, this was shown to be caused, in part, by action of heat shock proteins. Interestingly, treatment of oxidized LDL–stimulated DC with the anticoagulant Annexin A5 caused the DC to produce both IL-10 and transforming growth factor-β, which promoted differentiation of naive T cells to Treg cells in vitro. A second article explored how toll-like receptor (TLR) 9 signaling in myeloid cells protected mice against atherosclerosis.54 Although the exact mechanisms for the increased atherosclerosis in TLR9−/− apoE−/− mice are unclear, the data support the notion that TLR9 signaling may be atheroprotective: in the absence of TLR9 signaling, there is an accumulation of DC in atherosclerotic lesions that cause recruitment and activation of CD4+ T cells. Related to the above work on Tim-3, these investigators also found an increase in Tim-3 in the atherosclerotic lesions of TLR9-deficient mice, supporting the proatherogenic role for Tim-3 noted above.In sum, new work published in ATVB showing a protective role for Tregs in other vascular diseases, including aneurysm, support the notion that Tregs serve a protective role in vascular disease. New studies in mice and humans with T2D or obesity suggest that adipose depots are hotspots for immune regulation, with increased myeloid cell content and supporting active CD4 and CD8 lymphocyte recruitment to these fat depots. Understanding the functions of lymphocytes in adipose tissue may aid in preventing complications associated with obesity and T2D. Finally, new mechanisms for how lymphocytes may affect atherosclerosis are emerging, including myeloid cell-lymphocyte cross talk in the artery wall, thus, shedding light on possible new therapies for cardiovascular disease.Innate LymphocytesThe other lymphocytes, or unusual suspects, as classified by Reardon et al55 in 2005, include γδ lymphocytes, NKT cells, and NK cells. These cells make up a small percentage of lymphocytes, but they seem to pack a powerful punch, and as such, should not be underestimated in disease causation or protection. γδ lymphocytes possess the γδ T-cell receptor and are enriched in skin and in tissues during inflammation. Many γδ cells do not require antigen processing and presentation in the context of major histocompatibility complex molecules to respond to antigen and many recognize nonpeptide antigens, including phosphorylated nucleotides. In the context of atherosclerosis, γδ cells producing IL-17 were shown to be significantly elevated by ≈3-fold in aortas of apoE−/− mice fed a Western diet for 15 weeks.33 However, we studied early atherosclerosis development in T-cell receptor δ−/− apoE−/− double knockout mice and found no differences in atherosclerosis in mice lacking γδ cells, suggesting that they play a minor role, at least in early atherogenesis.56 NKT cells possess an invariant T-cell receptor that recognizes self and foreign lipid antigens presented by the class I–like molecule CD1d. The unique ability of NKT cells to recognize lipid antigens presented by CD1d suggests that they may play an important role in atherosclerosis, which is considered to be a lipid-driven disease. Most studies have reported that NKT cells are proatherogenic,57–64 including a recent study by Li et al.65 A recent review on NKT cells in atherosclerosis by Bondarenko et al66 was just published, and interested readers are encouraged to study this article. Recently in ATVB, the absence of NKT cells in liver of Jα18-deficient mice that lack NKT cells was associated with fewer and smaller adipocytes and increased lipolysis in adipose tissue, suggesting that NKT cells in liver can function to influence lipid metabolism in adipose.67 However, CD1d-deficient mice (which also lack NKT cells) had increased adiposity,68 suggesting that NKT cells may prevent metabolic dysfunction. More studies are needed to sort out these differences. Finally, NK cells, which are innate lymphocytes that do not possess a T-cell receptor and function early in the immune response to kill viruses and other pathogens, may also be important in atherosclerosis. A recent study by Selathurai et al69 reports that depletion of NK cells in mice using anti–Asialo-GM1 antibodies attenuated atherosclerosis in ApoE−/− mice. In support of this notion is a recent human study in ATVB that shows that a subset of NK cells expressing CD94 was associated with increased risk of plaque rupture.70 Kossmann et al71 also showed in mice that NK cells were involved in angiotensin II–mediated vascular dysfunction. These unusual lymphocyte suspects are being studied more and more in the context of vascular diseases, and it is becoming clear that these minor lymphocyte subsets play an important role in regulating vascular immunity.B LymphocytesThe roles that B lymphocytes play in atherogenesis have been studied less than the roles of T lymphocytes to date, but the past few years have been clearly the time of the B cell. B1 and B2 cells are 2 main families of B cells. A review article on targeting B cells in atherosclerosis was recently published in ATVB,72 and the reader is referred to that article for detailed information. Early on, B2 cells were thought to be atheroprotective73,74 and this has been confirmed recently in an apoE−/− mouse model that examined resident B cells in aorta.75 However, B2 cells have also been shown to be proatherogenic,74,76 so the role of B cells in atherosclerosis remains somewhat controversial. However, multiple studies support the concept that B1 cells are atheroprotective because of their production of natural IgM antibodies. A recent study in ATVB showed that mice lacking Id3 had fewer B1-a cells77 and reduced serum levels of the natural antibody E0678 that recognizes the phosphocholine headgroup of oxidized phospholipids.77 B1-a cell proliferation was found to be caused by Id3-mediated regulation of IL-5 production by natural helper cells, another innate lymphoid cell.77 In humans, CD19+ B-cell subsets have now been associated with risk of stroke. CD19+CD86+ B cells in blood were associated with higher incidence of developing stroke, and CD19+CD40+ B cells were associated with lower incidence of stroke risk in a cardiovascular cohort of the Malmo Diet and Cancer Study.79 Finally, Karper et al80 have found a link between TLR4 signaling and B-cell numbers and activation in atherosclerosis. Taken together, these studies suggest that B-cell subsets play a critical role in atherosclerosis and mechanisms that influence B-cell function, including transcription factors and receptors, including TLRs, are likely important mediators of atherosclerosis.SummaryIn ATVB, new studies this year continue to expand our knowledge of lymphocytes in atherosclerosis and in other vascular diseases. Also, several studies reported new mechanisms for how lymphocytes, including B cells and innate lymphocyte subsets, affect atherosclerosis and vascular disease.Sources of FundingResearch in the Hedrick laboratory is supported by National Institutes of Health grants P01 HL055798, R01 HL112276, R01 HL085790, R01 HL097368, the American Heart Association, and the American Diabetes Association.DisclosuresNone.FootnotesCorrespondence to Catherine C. Hedrick, PhD, Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, 9420 Athena Cir, La Jolla, CA 92037. E-mail [email protected]References1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.BMJ. 2000; 321:405–412.CrossrefMedlineGoogle Scholar2. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults.JAMA. 1999; 281:1291–1297.CrossrefMedlineGoogle Scholar3. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000.Ann Intern Med. 2007; 147:149–155.CrossrefMedlineGoogle Scholar4. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, Jacobs DR, Wu C, Saad MF, Szklo M. Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).Diabetes Care. 2007; 30:2951–2956. doi: 10.2337/dc07-1042.CrossrefMedlineGoogle Scholar5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study.JAMA. 1979; 241:2035–2038.CrossrefMedlineGoogle Scholar6. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.Diabetes Care. 1979; 2:120–126.CrossrefMedlineGoogle Scholar7. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis.Diabetes. 1995; 44:369–374.CrossrefMedlineGoogle Scholar8. Gleissner CA, Galkina E, Nadler JL, Ley K. Mechanisms by which diabetes increases cardiovascular disease.Drug Discov Today Dis Mech. 2007; 4:131–140. doi: 10.1016/j.ddmec.2007.12.005.CrossrefMedlineGoogle Scholar9. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.Arteriosclerosis. 1986; 6:131–138.LinkGoogle Scholar10. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques.Atherosclerosis. 1988; 72:135–141.CrossrefMedlineGoogle Scholar11. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque.Am J Pathol. 1989; 135:169–175.MedlineGoogle Scholar12. Hansson GK. Atherosclerosis–an immune disease: The Anitschkov Lecture 2007.Atherosclerosis. 2009; 202:2–10. doi: 10.1016/j.atherosclerosis.2008.08.039.CrossrefMedlineGoogle Scholar13. Hansson GK. Regulation of immune mechanisms in atherosclerosis.Ann N Y Acad Sci. 2001; 947:157–165; discussion 165.CrossrefMedlineGoogle Scholar14. Tobias P, Curtiss LK. Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis.J Lipid Res. 2005; 46:404–411. doi: 10.1194/jlr.R400015-JLR200.CrossrefMedlineGoogle Scholar15. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice.Arterioscler Thromb Vasc Biol. 2001; 21:1011–1016.LinkGoogle Scholar16. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice.Circulation. 2003; 108:1232–1237. doi: 10.1161/01.CIR.0000089083.61317.A1.LinkGoogle Scholar17. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice.Nat Med. 2006; 12:178–180. doi: 10.1038/nm1343.CrossrefMedlineGoogle Scholar18. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses.Proc Natl Acad Sci U S A. 2005; 102:1596–1601. doi: 10.1073/pnas.0409015102.CrossrefMedlineGoogle Scholar19. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule.Circulation. 2006; 114:2047–2055. doi: 10.1161/CIRCULATIONAHA.106.633263.LinkGoogle Scholar20. Gotsman I, Gupta R, Lichtman AH. The influence of the regulatory T lymphocytes on atherosclerosis.Arterioscler Thromb Vasc Biol. 2007; 27:2493–2495. doi: 10.1161/ATVBAHA.107.153064.LinkGoogle Scholar21. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes.Circ Res. 2002; 90:1064–1071.LinkGoogle Scholar22. Schiller NK, Boisvert WA, Curtiss LK. Inflammation in atherosclerosis: lesion formation in LDL receptor-deficient mice with perforin and Lyst(beige) mutations.Arterioscler Thromb Vasc Biol. 2002; 22:1341–1346.LinkGoogle Scholar23. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis.Clin Immunol. 2010; 134:33–46. doi: 10.1016/j.clim.2009.07.002.CrossrefMedlineGoogle Scholar24. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.Proc Natl Acad Sci U S A. 1995; 92:3893–3897.CrossrefMedlineGoogle Scholar25. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.Am J Pathol. 1996; 149:675–685.MedlineGoogle Scholar26. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice.Circulation. 2000; 102:2919–2922.LinkGoogle Scholar27. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis.Arterioscler Thromb Vasc Biol. 2006; 26:864–870. doi: 10.1161/01.ATV.0000206122.61591.ff.LinkGoogle Scholar28. Zhou X. CD4+ T cells in atherosclerosis.Biomed Pharmacother. 2003; 57:287–291.CrossrefMedlineGoogle Scholar29. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia.Circulation. 2001; 103:2610–2616.LinkGoogle Scholar30. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.Atherosclerosis. 1999; 145:33–43.CrossrefMedlineGoogle Scholar31. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis.J Innate Immun. 2010; 2:325–333. doi: 10.1159/000314626.CrossrefMedlineGoogle Scholar32. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice.J Immunol. 2009; 183:8167–8175. doi: 10.4049/jimmunol.0901126.CrossrefMedlineGoogle Scholar33. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice.Circulation. 2010; 121:1746–1755. doi: 10.1161/CIRCULATIONAHA.109.924886.LinkGoogle Scholar34. Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis?Curr Opin Lipidol. 2010; 21:404–408. doi: 10.1097/MOL.0b013e32833dc7f9.CrossrefMedlineGoogle Scholar35. Taleb S, Tedgui A, Mallat Z. Il-17 and th17 cells in atherosclerosis: subtle and contextual roles.Arterioscler Thromb Vasc Biol. 2015; 35:258–264.LinkGoogle Scholar36. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice.Biochem Biophys Res Commun. 2009; 388:261–265. doi: 10.1016/j.bbrc.2009.07.152.CrossrefMedlineGoogle Scholar37. Entin-Meer M, Afek A, George J. Regulatory T-cells, FoxP3 and atherosclerosis.Adv Exp Med Biol. 2009; 665:106–114.CrossrefMedlineGoogle Scholar38. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis.J Intern Med. 2008; 263:489–499. doi: 10.1111/j.1365-2796.2008.01944.x.CrossrefMedlineGoogle Scholar39. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice.Circulation. 2013; 127:1028–1039. doi: 10.1161/CIRCULATIONAHA.112.001347.LinkGoogle Scholar40. Zhou J, Dimayuga PC, Zhao X, Yano J, Lio WM, Trinidad P, Honjo T, Cercek B, Shah PK, Chyu KY. CD8(+)CD25(+) T cells reduce atherosclerosis in apoE(-/-) mice.Biochem Biophys Res Commun. 2014; 443:864–870. doi: 10.1016/j.bbrc.2013.12.057.CrossrefMedlineGoogle Scholar41. Li J, Ley K. Lymphocyte migration into atherosclerotic plaque.Arterioscler Thromb Vasc Biol. 2015; 35:40–49. doi: 10.1161/ATVBAHA.114.303227.LinkGoogle Scholar42. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia.Circulation. 2011; 124:185–195. doi: 10.1161/CIRCULATIONAHA.110.006411.LinkGoogle Scholar43. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity.Arterioscler Thromb Vasc Biol. 2009; 29:843–849. doi: 10.1161/ATVBAHA.108.183442.LinkGoogle Scholar44. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response.Cell. 2008; 134:97–111. doi: 10.1016/j.cell.2008.04.052.CrossrefMedlineGoogle Scholar45. Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation.J Immunol. 2010; 184:173–183. doi: 10.4049/jimmunol.0902372.CrossrefMedlineGoogle Scholar46. Ait-Oufella H, Wang Y, Herbin O, Bourcier S, Potteaux S, Joffre J, Loyer X, Ponnuswamy P, Esposito B, Dalloz M, Laurans L, Tedgui A, Mallat Z. Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice.Arterioscler Thromb Vasc Biol. 2013; 33:2374–2379. doi: 10.1161/ATVBAHA.113.301280.LinkGoogle Scholar47. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H, Hui Yen Chng M, Engleman E. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans.Arterioscler Thromb Vasc Biol. 2014; 34:2637–2643. doi: 10.1161/ATVBAHA.114.304636.LinkGoogle Scholar48. Rocha VZ, Folco EJ, Ozdemir C, Sheikine Y, Christen T, Sukhova GK, Tang EH, Bittencourt MS, Santos RD, Luster AD, Cohen DE, Libby P. CXCR3 controls T-cell accumulation in fat inflammation.Arterioscler Thromb Vasc Biol. 2014; 34:1374–1381. doi: 10.1161/ATVBAHA.113.303133.LinkGoogle Scholar49. Jiang E, Perrard XD, Yang D, Khan IM, Perrard JL, Smith CW, Ballantyne CM, Wu H. Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue.Arterioscler Thromb Vasc Biol. 2014; 34:34–43. doi: 10.1161/ATVBAHA.113.302077.LinkGoogle Scholar50. Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM, Orr AW, Orr W, Traylor JG, Rogers T, Cornwell W, Berglund LM, Goncalves I, Gomez MF, Autieri MV. Attenuation of experimental atherosclerosis by interleukin-19.Arterioscler Thromb Vasc Biol. 2013; 33:2316–2324. doi: 10.1161/ATVBAHA.113.301521.LinkGoogle Scholar51. Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, van Puijvelde GH. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis.Arterioscler Thromb Vasc Biol. 2013; 33:2558–2565. doi: 10.1161/ATVBAHA.113.301879.LinkGoogle Scholar52. Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, Nilsson J, Björkbacka H. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke.Arterioscler Thromb Vasc Biol. 2013; 33:637–644. doi: 10.1161/ATVBAHA.112.300871.LinkGoogle Scholar53. Liu A, Ming JY, Fiskesund R, Ninio E, Karabina SA, Bergmark C, Frostegård AG, Frostegård J. Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins.Arterioscler Thromb Vasc Biol. 2015; 35:197–205. doi: 10.1161/ATVBAHA.114.304342.LinkGoogle Scholar54. Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-